Differentiated thyroid cancer patients who receive radioiodine (RAI) treatment after surgery have increased relative survival rates compared to those who do not receive the treatment. According to new research published in the April issue of The Journal of Nuclear Medicine, the clear trend for a higher long-term survival rate is observed in subgroups of patients with low- and intermediate-risk disease, while there is special benefit in high-risk diseases. These findings confirm the benefit of RAI therapy for thyroid cancer patients and provide useful information for physicians to consider when determining optimal treatment.
This article was originally published on MedicalXpress.com
